Separation type: Bridge Ion Separation Technology, or BIST™ by SIELC Technologies
HPLC Method for Analysis Fitusiran on OligoMg Column by SIELC Technologies

Fitusiran is a relatively new therapeutic agent developed for the treatment of hemophilia A and B, including in patients with or without inhibitors.
Using SIELC’s newly introduced BIST™ method, this oligonucleotide can be retained on a OligoMg column. Using this new and unique analysis method, oligonucleotide can be separated, retained, and detected at 260 nm.
Please read more on oligonucleotides analysis by HPLC in our June 2024 newsletter.
Condition
Column | OligoMg, 4.6 x 100 mm, 3 µm, 100 A |
Mobile Phase | Gradient MeCN 60-10%, 10 min |
Buffer | none |
Flow Rate | 1.0 ml/min |
Detection | UV 260 nm |
Description
Class of Compounds | Drug, RNA |
Analyzing Compounds | Fitusiran |